This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionEfficacy and safety of intravenous thrombolysis (IVT) in patients undergoing mechanical thrombectomy (MT) is still debatable. ResultsWe included four randomized controlled trials with 1176 patients.
Stroke, Volume 55, Issue Suppl_1 , Page A97-A97, February 1, 2024. vs 19.6%, p=0.002) and a past-history of stroke/TIA (36% vs 25%, p<0.001) when compared to non-AC group. Chronic embolic (non-lacunar) infarcts on imaging were more common among AIS-despite-AC (34.5% Patients who had AIS-despite-AC were younger (76.8+11
Stroke, Ahead of Print. BACKGROUND:Intravenous injection of alteplase, a recombinant tPA (tissue-type plasminogen activator) as a thrombolytic agent has revolutionized ischemic stroke management. However, when associated to tPAWTlittermates, tPANullmice had similar perfusion deficits, but less severe brain infarcts.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionPosterior circulation strokes account for 20% of ischemic strokes (1). Optimal management for posterior circulation strokes has been studied less than for anterior circulation strokes (2). hours prior to arrival.
Stroke, Volume 55, Issue Suppl_1 , Page ATP195-ATP195, February 1, 2024. Previous studies have noted that ICAD-related LVOs, compared to embolic occlusions, have longer procedural times and lower successful reperfusion rates. Successful recanalization was defined as Thrombolysis in Cerebral Ischemia score ≥2b.
Stroke, Volume 55, Issue Suppl_1 , Page AWP288-AWP288, February 1, 2024. Results:Between 2017 and 2022, 1,283,435 CVD cases were notified (SAH=4,7%; ICH= 8.8%; and ischemic stroke=86.5%). Results:Between 2017 and 2022, 1,283,435 CVD cases were notified (SAH=4,7%; ICH= 8.8%; and ischemic stroke=86.5%). were Male and 47.6%
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. 1% of all strokes, with complete or posterior spinal cord involvement detailed in the case below being even rarer. IntroductionSpinal cord infarctions (SCI) are scarce entities, constituting only 0.3‐1%
Stroke, Volume 55, Issue Suppl_1 , Page ATP187-ATP187, February 1, 2024. First pass effect (FPE) was defined as a modified Thrombolysis in Cerebral Infarction (mTICI) score ≥ 2C after the first pass.Results:A total of 1,508 patients were included, of whom 231 (15.3%) were in the BGC group and 1,277 (84.7%) were in the Non-BGC group.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Besides various demographic parameters, we collected final recanalization rates with first pass effect [using modified Thrombolysis in Cerebral Infarction (TICI) score]. aspiration catheter over stent bare wire to “pinch” the primal end of the clot.
The International Stroke Conference 2024 will be held Feb. According to program planners with the American Stroke Association, a division of the American Heart Association, findings from late-breaking science will include multiple high profile randomized clinical trials like RESILIENT-Extend, EMBOLISE, STEM, ZODIAC, among many others.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content